Interventional Cardiology Clinical Trials

Condition: 

Stroke

Condition: 

Coronary artery disease, peripheral vascular disease, cancers

Key Inclusion Criteria:

• At least 18 years old with body mass index less than 30
• Diagnosed with or undergoing evaluation for cardiovascular, nervous system diseases or solid-organ cancers

Summary:

Using the hybrid Siemens Biograph mMr (PET-MR) scanner, researchers simultaneously acquire MR and PET data across the whole body. Biomedical Imaging Research Institute scientists focus on developing new imaging techniques to answer a wide array of research and clinical questions, where producing a single scan that reveals both functional and anatomical information would create a more complete diagnostic tool. In collaboration with medical specialists, pulse sequences (software) are validated in patients undergoing evaluation for numerous diseases, including many types of heart disease, peripheral and intracranial (brain) neurological diseases, cancers, spine problems, urology and other nervous system disorders. The long-term goal of this study is to develop new techniques that would translate to clinical significance.

Condition: 

Mitral Valve Regurgitation

Condition: 

Cardiac Imaging

Key Inclusion Criteria:

• Patients undergoing a self-referred or physician-referred cardiac imaging procedure for any standard clinical indication

Summary:

The purpose of this research registry is to develop an organized system of information (demographic, historical, clinical, imaging and outcomes) from patients undergoing cardiac imaging procedures for use in ongoing and future research. The registry will allow qualified investigators at Cedars-Sinai to conduct analyses and write manuscripts that are critical in improving the ability to detect, accurately assess, and possibly prevent adverse outcomes of heart disease.

Condition: 

Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease (Heart), Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease

Condition: 

Atherosclerotic cardiovascular disease, hypercholesterolemia

Key Inclusion Criteria:

• Evidence by cardiac computed tomography angiography of noncalcified coronary artery plaque and thoracic aorta atherosclerosis 
• Indications for evolocumab treatment

Summary:

This study focuses on patients who have clinical atherosclerotic cardiovascular disease (ASCVD) or high cholesterol levels and are allergic to statins, or who have been diagnosed with primary hypercholesterolemia or homozygous familial hypercholesterolemia (genetic disorder causing high cholesterol levels and early heart disease). The purpose of the study is to evaluate the changes, if any, in coronary plaque volumes and its composition in patients who are treated with a drug called evolocumab. To help evaluate the effect of evolocumab, researchers will ask patients who are scheduled to start taking evolocumab plus another cholesterol-lowering medication (such as a statin) to undergo diagnostic testing, including non-invasive coronary computed tomography angiography scans and positron emission tomography (PET) scans.

Condition: 

Homozygous Familial Hypercholesterolemia

Condition: 

Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction

Condition: 

Tricuspid Valve Insufficiency

Condition: 

Homozygous Familial Hypercholesterolemia, HoFH

Condition: 

Atrial Fibrillation

Condition: 

Coronary Microvascular Dysfunction

Condition: 

Hypercholesterolemia

Condition: 

Mitral Valve Regurgitation